tiprankstipranks
pc:acc50

Accro Bioscience

Therapeutics
A clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulatory cell death for immune-mediated diseases. The company is advancing a multi-asset pipeline including AC-101, a RIPK2 inhibitor in development for ulcerative colitis, aiming to deliver targeted therapies for inflammatory and autoimmune conditions.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation―
Estimated Valuation―
Total Amount Raised$50M
Total Amount Raised$50M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$50M
Latest Funding Amount$50M
Latest Funding RoundSeries C
Latest Funding RoundSeries C
Post-Money Valuation―
Post-Money Valuation―

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
May 19, 2026
Series C
$50.00M
―

Investors

Investor Name
Funding Round
OrbiMed
Series C
TCG Crossover (TCGX)
Series C
LAV
Series C
Cenova Capital
Series C
Shenzhen Capital Group (SCGC)
Series C
Oriza Holdings (Oriza)
Series C

Related News and Analysis

ClickHouse Highlights Advanced Data Sampling Capabilities for Analytics Workloads

ClickHouse Highlights Advanced Data Sampling Capabilities for Analytics Workloads

According to a recent LinkedIn post from ClickHouse, the company is highlighting a new primer that explains how...
3h ago
CLHSE
1Password Highlights Mentorship and Talent Development Focus

1Password Highlights Mentorship and Talent Development Focus

According to a recent LinkedIn post from 1Password, the company is highlighting its internal mentorship program through the...
3h ago
1PASS
Flexport Highlights Persistent Cost and Capacity Pressures in Global Air Freight

Flexport Highlights Persistent Cost and Capacity Pressures in Global Air Freight

According to a recent LinkedIn post from Flexport, the company’s air freight leadership is drawing attention to persistent...
3h ago
FLEXP
Rivian R2 Launch Viewed as Key Test for Profitability and Equity Upside

Rivian R2 Launch Viewed as Key Test for Profitability and Equity Upside

According to a recent LinkedIn post from EV Co, Rivian’s forthcoming R2 SUV is being framed by analysts...
3h ago
EVCOM
Nio Targets Online Smear Campaigns Amid New Model Launches and Profit Push

Nio Targets Online Smear Campaigns Amid New Model Launches and Profit Push

According to a recent LinkedIn post from EV Co, Chinese EV maker Nio has reportedly referred several alleged...
3h ago
EVCOM
Fictiv Targets Battery and EV Manufacturing Opportunities at BATTECH Event

Fictiv Targets Battery and EV Manufacturing Opportunities at BATTECH Event

A LinkedIn post from Fictiv highlights the company’s planned presence at the BATTECH by WeAutomotive Group event in...
3h ago
FICTI
Xiaomi EV Targets Broader Market With YU7 Lineup and New Pricing Ahead of 2026 Shenzhen Auto Show

Xiaomi EV Targets Broader Market With YU7 Lineup and New Pricing Ahead of 2026 Shenzhen Auto Show

According to a recent LinkedIn post from EV Co, Xiaomi EV plans to showcase its full electric vehicle...
3h ago
EVCOM
Babylist Tracks Emerging Baby-Gear Trends at ABC Kids Expo

Babylist Tracks Emerging Baby-Gear Trends at ABC Kids Expo

According to a recent LinkedIn post from Babylist, the company’s team attended the ABC Kids Expo to evaluate...
3h ago
BABYL
Bobbie Elevates Policy-Driven Social Impact Strategy in Infant Nutrition

Bobbie Elevates Policy-Driven Social Impact Strategy in Infant Nutrition

According to a recent LinkedIn post from Bobbie, the company is emphasizing a long-term social impact strategy centered...
3h ago
BOBBI
Ford Redirects Kentucky Gigafactory Toward Grid-Scale Energy Storage Production

Ford Redirects Kentucky Gigafactory Toward Grid-Scale Energy Storage Production

According to a recent LinkedIn post from EV Co, Ford Motor Company has assumed a $3.8 billion U.S....
3h ago
EVCOM